Synedgen Completes IND-Enabling Studies for Two Parallel Programs for Lead Asset MIIST305
Synedgen, a biotechnology company using glycopolymer chemistry to develop therapeutics that enhance and control signaling in the innate immune system, today announced the initiation of a randomized controlled trial (RCT) to test the safety and effectiveness of SynePureâ„¢ Wound Cleanser (SynePure) in combination with Catasynâ„¢ Advanced Technology Hydrogel (Catasyn) for the treatment of superficial partial-thickness burn wounds.
CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, a biotechnology company using glycopolymer chemistry to develop therapeutics that enhance and control signaling in the innate immune system, today announced the initiation of a randomized controlled trial (RCT) to test the safety and effectiveness of SynePure™ Wound Cleanser (SynePure) in combination with Catasyn™ Advanced Technology Hydrogel (Catasyn) for the treatment of superficial partial-thickness burn wounds.
CLAREMONT, Calif.--(BUSINESS WIRE)--Synedgen, a biotechnology company using glycopolymer chemistry to develop drugs that enhance and control signaling in the innate immune system, today announced supplemental funding from the National Eye Institute (NEI) of the NIH to identify a lead molecule from the company’s ocular mustard gas injury program to move into animal studies.